Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
© Synapse Social LLC, 2026
Politique de confidentialité
Retour
Langue
Français
Français
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers | Synapse
March 3, 2026
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers
AB
Alice Bertaina
RB
Rosa Bacchetta
Lucile Packard Children's Hospital
DS
David C. Shyr
Lucile Packard Children's Hospital
See all
Key Points
Leukemia-free survival improves significantly with T-allo10 cell addback after abdepleted-hsct.
The analysis shows a marked increase in lasting leukemia-free survival reaching 80% at one year.
Assessment using immune regulation biomarkers reveals distinct profiles after T-allo10 treatment.
Implications suggest novel therapeutic strategies may enhance outcomes in leukemia treatment.
Demander à l'IA
Mark Helpful
Like
Save
Bookmark
Relay
Share
Demander à l'IA
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Bertaina et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760adc6e9836116a2da9f
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.145